CCL26 and Alzheimer disease: However, treatment with either tofacitinib or JTE-052 successfully suppressed IL-4-induced upregulation of the mRNA of CCL26 (Figure 2C,F), a representative JAK/STAT6 axis-mediated chemokine [24,25] reflecting disease activity in AD [26], in a dose-dependent manner.